AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Perspectives
This section features opinion pieces, reflections, and expert commentary on timely or overlooked issues in cancer care, research, and the oncology workforce.
The First Positive Phase 3 Trial Ever in Dedifferentiated Liposarcoma Changes a Difficult Conversation
By David Savage, MD
Dedifferentiated liposarcoma has had no positive phase 3 trial in its history, and existing chemotherapy options rarely delay progression beyond a few months.
The First Positive Phase 3 Trial Ever in Dedifferentiated Liposarcoma Changes a Difficult Conversation
By David Savage, MD
Dedifferentiated liposarcoma has had no positive phase 3 trial in its history, and existing chemotherapy options rarely delay progression beyond a few months.
The First Positive Phase 3 Trial Ever in Dedifferentiated Liposarcoma Changes a Difficult Conversation
By David Savage, MD
Dedifferentiated liposarcoma has had no positive phase 3 trial in its history, and existing chemotherapy options rarely delay progression beyond a few months.
Will Multispecific CAR T-Cell Therapy Replace Single-Target CD19 Treatment in Lymphoma?
By Saurabh Dahiya, MD, FACP
CD19-directed CAR T-cell therapy has transformed care for B-cell lymphomas, but most patients still relapse, often due to loss of the CD19 target.
Will Multispecific CAR T-Cell Therapy Replace Single-Target CD19 Treatment in Lymphoma?
By Saurabh Dahiya, MD, FACP
CD19-directed CAR T-cell therapy has transformed care for B-cell lymphomas, but most patients still relapse, often due to loss of the CD19 target.
Will Multispecific CAR T-Cell Therapy Replace Single-Target CD19 Treatment in Lymphoma?
By Saurabh Dahiya, MD, FACP
CD19-directed CAR T-cell therapy has transformed care for B-cell lymphomas, but most patients still relapse, often due to loss of the CD19 target.
Early-Stage Breast Cancer: Why Fewer Patients Need Chemotherapy, and More Need CDK4/6 Inhibitors
By Ruta Rao, MD
Genomic testing is increasingly identifying which early-stage, hormone receptor-positive breast cancer patients can safely skip chemotherapy, even among some node-positive premenopausal women.
Early-Stage Breast Cancer: Why Fewer Patients Need Chemotherapy, and More Need CDK4/6 Inhibitors
By Ruta Rao, MD
Genomic testing is increasingly identifying which early-stage, hormone receptor-positive breast cancer patients can safely skip chemotherapy, even among some node-positive premenopausal women.
Early-Stage Breast Cancer: Why Fewer Patients Need Chemotherapy, and More Need CDK4/6 Inhibitors
By Ruta Rao, MD
Genomic testing is increasingly identifying which early-stage, hormone receptor-positive breast cancer patients can safely skip chemotherapy, even among some node-positive premenopausal women.
Beyond G12C: KRAS Lung Cancer Is About to Become a Toolkit, Not a Single Target
By Benjamin Herzberg, MD
KRAS G12C is not the only KRAS mutation worth worrying about, and I think that idea is very close to being obsolete.
Beyond G12C: KRAS Lung Cancer Is About to Become a Toolkit, Not a Single Target
By Benjamin Herzberg, MD
KRAS G12C is not the only KRAS mutation worth worrying about, and I think that idea is very close to being obsolete.
Beyond G12C: KRAS Lung Cancer Is About to Become a Toolkit, Not a Single Target
By Benjamin Herzberg, MD
KRAS G12C is not the only KRAS mutation worth worrying about, and I think that idea is very close to being obsolete.
Head and Neck Cancer: New Antibodies After Checkpoint Failure, and Rethinking Immunotherapy Plus Radiation
By Weining Ken Zhen, MD
Developing new strategies for advanced head and neck cancer after checkpoint inhibitor and chemotherapy failures.
Head and Neck Cancer: New Antibodies After Checkpoint Failure, and Rethinking Immunotherapy Plus Radiation
By Weining Ken Zhen, MD
Developing new strategies for advanced head and neck cancer after checkpoint inhibitor and chemotherapy failures.
Head and Neck Cancer: New Antibodies After Checkpoint Failure, and Rethinking Immunotherapy Plus Radiation
By Weining Ken Zhen, MD
Developing new strategies for advanced head and neck cancer after checkpoint inhibitor and chemotherapy failures.
Colorectal Cancer: Exercise Pays for Itself, Aspirin's Role Stays Murky, and Some Patients Can Stop Immunotherapy Early
By Rishi Batra, MD, MBA
Three abstracts from this year's ASCO meeting speak to very different parts of the colorectal cancer journey
Colorectal Cancer: Exercise Pays for Itself, Aspirin's Role Stays Murky, and Some Patients Can Stop Immunotherapy Early
By Rishi Batra, MD, MBA
Three abstracts from this year's ASCO meeting speak to very different parts of the colorectal cancer journey
Colorectal Cancer: Exercise Pays for Itself, Aspirin's Role Stays Murky, and Some Patients Can Stop Immunotherapy Early
By Rishi Batra, MD, MBA
Three abstracts from this year's ASCO meeting speak to very different parts of the colorectal cancer journey
Triple Negative Breast Cancer Gets Real Momentum: What ASCO 2026 Changes for Patients Now
By Amulya Yellala, MD
Triple negative breast cancer has long been described as hard to treat and fast moving, but this year's data, much of it long-term follow-up on treatments already reshaping practice, continues to build real momentum.
Triple Negative Breast Cancer Gets Real Momentum: What ASCO 2026 Changes for Patients Now
By Amulya Yellala, MD
Triple negative breast cancer has long been described as hard to treat and fast moving, but this year's data, much of it long-term follow-up on treatments already reshaping practice, continues to build real momentum.
Triple Negative Breast Cancer Gets Real Momentum: What ASCO 2026 Changes for Patients Now
By Amulya Yellala, MD
Triple negative breast cancer has long been described as hard to treat and fast moving, but this year's data, much of it long-term follow-up on treatments already reshaping practice, continues to build real momentum.
Cellular Therapy Gets More Precise: In Vivo CAR T, a New Treg Therapy, and Menin Inhibitor Maintenance
By Moataz Ellithi, MD
Cellular therapy for blood cancers is moving in two directions at once: toward manufacturing CAR T-cells directly inside a patient's body rather than in a lab
Cellular Therapy Gets More Precise: In Vivo CAR T, a New Treg Therapy, and Menin Inhibitor Maintenance
By Moataz Ellithi, MD
Cellular therapy for blood cancers is moving in two directions at once: toward manufacturing CAR T-cells directly inside a patient's body rather than in a lab
Cellular Therapy Gets More Precise: In Vivo CAR T, a New Treg Therapy, and Menin Inhibitor Maintenance
By Moataz Ellithi, MD
Cellular therapy for blood cancers is moving in two directions at once: toward manufacturing CAR T-cells directly inside a patient's body rather than in a lab
Managing Bispecific T-Cell Engager Toxicity: CRS and ICANs in Practice
By Allison Hamner, PharmD, BCPS
Bispecific T-cell engagers (BiTEs) offer major efficacy in hematologic malignancies, but their signature toxicities—cytokine release syndrome (CRS) and ICANS—require real-time vigilance and management similar to CAR T-cell therapy.
Managing Bispecific T-Cell Engager Toxicity: CRS and ICANs in Practice
By Allison Hamner, PharmD, BCPS
Bispecific T-cell engagers (BiTEs) offer major efficacy in hematologic malignancies, but their signature toxicities—cytokine release syndrome (CRS) and ICANS—require real-time vigilance and management similar to CAR T-cell therapy.
Managing Bispecific T-Cell Engager Toxicity: CRS and ICANs in Practice
By Allison Hamner, PharmD, BCPS
Bispecific T-cell engagers (BiTEs) offer major efficacy in hematologic malignancies, but their signature toxicities—cytokine release syndrome (CRS) and ICANS—require real-time vigilance and management similar to CAR T-cell therapy.
Multiple Myeloma at ASCO 2026: Bispecifics, CELMoDs, In Vivo CAR-T, and Early Intervention in Smoldering Disease
By Adeel M. Khan, MD, MPH, MS
Multiple myeloma had another eventful year at the 2026 ASCO Annual Meeting, with notable data across nearly every stage of disease
Multiple Myeloma at ASCO 2026: Bispecifics, CELMoDs, In Vivo CAR-T, and Early Intervention in Smoldering Disease
By Adeel M. Khan, MD, MPH, MS
Multiple myeloma had another eventful year at the 2026 ASCO Annual Meeting, with notable data across nearly every stage of disease
Multiple Myeloma at ASCO 2026: Bispecifics, CELMoDs, In Vivo CAR-T, and Early Intervention in Smoldering Disease
By Adeel M. Khan, MD, MPH, MS
Multiple myeloma had another eventful year at the 2026 ASCO Annual Meeting, with notable data across nearly every stage of disease